Interstitial Lung Disease and Obstructive Sleep Apnea

Study on the Clinical Characteristics of Interstitial Lung Disease and Obstructive Sleep Apnea

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05838183

Enrollment

Registered

2023-05-01

Start date

2019-09-01

Completion date

2026-12-31

Last updated

2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ILD OSA

Brief summary

Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease. All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively

Interventions

DIAGNOSTIC_TESTThe relationship between imaging and ROSE and NGS

The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* over 18 years old and under 80 years old. * Clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome. * Patient is conscious and capable of signing informed consent. * The patient may wear a polysomnograph.

Exclusion criteria

* malignant tumors. * severe heart failure. * uremia. * autoimmune diseases. * pulmonary embolism, and end-stage chronic obstructive pulmonary disease. * Patients with mental illnesscannot sign informed consent on their own.

Design outcomes

Primary

Measure	Time frame	Description
imaging changes and ROSE and NGS in patients	2Day	Relationship between imaging changes and ROSE and NGS in patients with interstitial lung disease

Secondary

Measure	Time frame	Description
Severity and biological examination of OSA patients	2Day	Classification of the severity of OSA and the relationship between positive results of biological or other tests

Countries

China

Contacts

CONTACTDan Liu

liudan_nkdx@163.com13920701949

CONTACTJing Feng

jingfeng_zyy@126.com13920500251

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026